Fingolimod Provides Long-Term Protection in Rodent Models of Cerebral Ischemia

Creative Commons License

Wei Y., Yemisci M., Kim H., Yung L. M., Shin H. K., Hwang S., ...Daha Fazla

ANNALS OF NEUROLOGY, cilt.69, sa.1, ss.119-129, 2011 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 69 Sayı: 1
  • Basım Tarihi: 2011
  • Doi Numarası: 10.1002/ana.22186
  • Dergi Adı: ANNALS OF NEUROLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.119-129
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Objective: The sphingosine-1-phosphate (S1P) receptor agonist fingolimod (FTY720), that has shown efficacy in advanced multiple sclerosis clinical trials, decreases reperfusion injury in heart, liver, and kidney. We therefore tested the therapeutic effects of fingolimod in several rodent models of focal cerebral ischennia. To assess the translational significance of these findings, we asked whether fingolimod improved long-term behavioral outcomes, whether delayed treatment was still effective, and whether neuroprotection can be obtained in a second species.